Aspire Biopharma Holdings (ASBP) Share-based Compensation (2025 - 2026)

Aspire Biopharma Holdings' (ASBP) quarterly Share-based Compensation came in at $13406.0 in Q1 2026, down 100.0% year-on-year from $14131.2 billion in Q1 2025, and up 142.9% on a QoQ basis from -$31250.0 in Q4 2025.

Aspire Biopharma Holdings (ASBP) Share-based Compensation (2025 - 2026) Analysis & Trends

Aspire Biopharma Holdings (ASBP) has 2 years of Share-based Compensation data on file, last reported at $13406.0 in Q1 2026.

  • On a quarterly basis, Share-based Compensation fell 100.0% year-over-year to $13406.0 in Q1 2026; TTM through Mar 2026 was -$14131.2 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $14.1 million, changed N/A from the prior year.
  • Share-based Compensation for Q1 2026 stood at $13406.0, up from -$31250.0 in the prior quarter.
  • Over the last five years, Share-based Compensation for ASBP reached as high as $14131.2 billion in Q1 2025 and fell as low as -$14131.2 billion in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 6.39 Mn
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 305,000.00
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 9.26 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 166.40 Mn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 257.40 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - 87.30 Mn
10 Aspire Biopharma Holdings 1.09 Mn -733,865.14 5,750.00 13,406.00

Historic Data

Download Data
DateValue
Mar 31, 2026 13,406.00
Mar 31, 2026 13,406.00
Dec 31, 2025 -31,250.00
Dec 31, 2025 -31,250.00
Jun 30, 2025 -14,131.24 Bn
Jun 30, 2025 -14,131.24 Bn
Mar 31, 2025 14,131.25 Bn
Mar 31, 2025 14,131.25 Bn